Get started
Work

Supplementary Figure 2B from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

Year: 2023
Type: supplementary-materials
Abstract: Figure S2B displays probability of progression-free survival over time in subgroups of patients with and without trisomy 12
DOI: 10.1158/1078-0432.22480020
Authors: Matthew S. Davids, Bryone J. Kuss, Peter Hillmen, Marco Montillo, Carol Moreno, James Essell, Nicole Lamanna, Zsolt Nagy, Constantine S. Tam, Stephan Stilgenbauer, Paolo Ghia, Julio Delgado, Stephanie Lustgarten, David T. Weaver, Hagop Youssoufian, Ulrich Jäger
Language: English
Field: Medicine
Open Access status: gold
OpenAlex ID: W4361815340
Cites:
Cited by:
Related to: 10